Abstract
The number of youns diabetics is increasing and therapeutic options for these patients are limited. Glucagon-like peptide-1 (GLP-1) is secreted from the gut after meals and enhances glucose-induced insulin secretion, inhibits glucagon secretion, suppresses appetite, and delays the gastric-emptying rate. GLP-1 analogs are already widely used in the adult population to improve glycemic control and induce weight loss in overweight subjects with type 2 diabetes. The glucose-lowering effects resulting from the inhibition of glucagon secretion and the gastric-emptying rate could be of clinical importance in type 1 diabetes. In this article we review clinical data regarding the use of GLP-1 receptor agonists in youth and address the potential benefits and safety aspects of these compounds. Large scale clinical trials are still needed in the pediatric population.
| Original language | English |
|---|---|
| Pages (from-to) | 324-327 |
| Number of pages | 4 |
| Journal | Pediatric Endocrinology Reviews |
| Volume | 11 |
| Issue number | 3 |
| State | Published - Mar 2014 |
| Externally published | Yes |
Keywords
- Children
- Diabetes mellitus
- GLP-1preparations
- Obesity
- Type 1
- Type 2
